AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32874106 — intervention group
Group type: COMPARATOR
Intervention: Inactive control group (CON)
Number of subjects: 44
Study 35886419 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle relaxation intervention
Number of subjects: 170
Study 35886419 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis intervention
Number of subjects: 170
Study 35886419 — intervention group
Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 170
Study 35886419 — intervention group
Group type: COMPARATOR
Intervention: Passive control group
Number of subjects: 170
Study 35886419 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions (muscle relaxation, hypnosis, active control)
Number of subjects: 170
Study 34967170 — intervention group
Group type: EXPERIMENTAL
Intervention: PPR-001
Number of subjects: 100
Study 34967170 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 35970431 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.003% AR-15512
Number of subjects: 122
Study 35970431 — intervention group
Group type: COMPARATOR
Intervention: 0.0014% AR-15512
Number of subjects: 122
Study 35970431 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 122
Study 34031020 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel monotherapy
Number of subjects: 833
Study 34031020 — intervention group
Group type: COMPARATOR
Intervention: DAPT
Number of subjects: 833
Study 35215467 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc biofortified flour
Number of subjects: 72
Study 35215467 — intervention group
Group type: COMPARATOR
Intervention: Control flour (not specified)
Number of subjects: 72
Study 32383748 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (15 mg for men and 12 mg for women, taken daily by mouth for 18 months)
Number of subjects: 254
Study 32383748 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 254
Study 32383748 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 254
Study 34208363 — intervention group
Group type: EXPERIMENTAL
Intervention: Support Group (SG) - 18 months of dietary and psychological support including Ten Top Tips (TTT), cognitive behavioral therapy (CBT), motivational interviewing (MI), nutritional education, and physical activity assessment
Number of subjects: 36
Study 34208363 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - no additional care
Number of subjects: 36
Study 32201442 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate 7.5 mg/week for 12 weeks
Number of subjects: 90
Study 32201442 — intervention group
Group type: COMPARATOR
Intervention: Pioglitazone 15 mg tablets once daily for 12 weeks
Number of subjects: 90
Study 32201442 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of methotrexate and pioglitazone
Number of subjects: 90
Study 35347091 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Acustimulation (TEA) at acupuncture point ST36 (chronic study)
Number of subjects: 53
Study 35347091 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Acustimulation (TEA) at acupuncture point ST36 (acute study)
Number of subjects: 53
Study 35347091 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Acustimulation (TEA) at acupuncture point ST36 (acute and chronic studies)
Number of subjects: 53
Study 35347091 — intervention group
Group type: COMPARATOR
Intervention: Sham-TEA (chronic study)
Number of subjects: 53
Study 34528557 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated concurrent chemoradiotherapy (ART) with 50 Gy/25#/4 weeks and cisplatin 40 mg/m2 weekly
Number of subjects: 90
Study 34528557 — intervention group
Group type: COMPARATOR
Intervention: Conventional concurrent chemoradiotherapy (control) with 50 Gy/25#/5 weeks and cisplatin 40 mg/m2 weekly
Number of subjects: 90
Study 32891126 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual diabetes clinic
Number of subjects: 100
Study 32891126 — intervention group
Group type: COMPARATOR
Intervention: Usual diabetes care
Number of subjects: 100
Study 35790961 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 573
Study 35790961 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 573
Study 33406277 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-1004-1239 (doses 1-200 mg)
Number of subjects: 48
Study 33406277 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 33406277 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-1004-1239
Number of subjects: 48
Study 33441798 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavender aroma during sleep
Number of subjects: 9
Study 33051029 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual cognitive behavioral therapy (ICBT) delivered in research settings
Number of subjects: 68
Study 33051029 — intervention group
Group type: COMPARATOR
Intervention: Individual cognitive behavioral therapy (ICBT) delivered in community settings
Number of subjects: 68
Study 35833274 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX + adalimumab
Number of subjects: 180
Study 35833274 — intervention group
Group type: COMPARATOR
Intervention: MTX + placebo
Number of subjects: 180
Study 33782020 — intervention group
Group type: EXPERIMENTAL
Intervention: Unite for a Better Life (UBL) intervention
Number of subjects: 6770
Study 32569033 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-layer Stockinette (29 patients)
Number of subjects: 56
Study 32569033 — intervention group
Group type: COMPARATOR
Intervention: Standard 2- to 3-layer Webril (27 patients)
Number of subjects: 56
Study 32569033 — intervention group
Group type: COMPARATOR
Intervention: Webril group
Number of subjects: 56
Study 32569033 — intervention group
Group type: EXPERIMENTAL
Intervention: Stockinette group
Number of subjects: 56
Study 32569033 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-layer Stockinette
Number of subjects: 56
Study 32569033 — intervention group
Group type: COMPARATOR
Intervention: Standard 2- to 3-layer Webril
Number of subjects: 56
Study 33886402 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual-based infographics with a day frame
Number of subjects: 268
Study 33886402 — intervention group
Group type: EXPERIMENTAL
Intervention: Text-based messages with a year frame
Number of subjects: 268
Study 33886402 — intervention group
Group type: COMPARATOR
Intervention: Visual-based infographics with a year frame
Number of subjects: 268
Study 33886402 — intervention group
Group type: COMPARATOR
Intervention: Text-based messages with a day frame
Number of subjects: 268
Study 32293992 — intervention group
Group type: EXPERIMENTAL
Intervention: Single pigtail suture stent (SPSS)
Number of subjects: 130
Study 32293992 — intervention group
Group type: COMPARATOR
Intervention: Double-pigtail ureteral stent (DPUS)
Number of subjects: 130
Study 33435992 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led support (intensive arm)
Number of subjects: 323
Study 33435992 — intervention group
Group type: COMPARATOR
Intervention: Standard care (standard arm)
Number of subjects: 323
Study 33435992 — intervention group
Group type: COMPARATOR
Intervention: Combined standard and observational arms
Number of subjects: 323
Study 32481255 — intervention group
Group type: EXPERIMENTAL
Intervention: Naesohwajung-tang (NHT)
Number of subjects: 116
Study 32481255 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 35995732 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 80
Study 35995732 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 80
Study 33789437 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-implemented augmented language intervention using AAC
Number of subjects: 109
Study 33789437 — intervention group
Group type: COMPARATOR
Intervention: Traditional spoken language intervention
Number of subjects: 109
Study 33055589 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with cisplatin and docetaxel, followed by concomitant chemoradiation therapy with cisplatin, docetaxel, and 45Gy, plus adjuvant cetuximab.
Number of subjects: 259
Study 34617827 — intervention group
Group type: EXPERIMENTAL
Intervention: DA + SDM video
Number of subjects: 0
Study 33989969 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone/Bupropion (NB) + antidepressants
Number of subjects: 8910
Study 33989969 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone/Bupropion (NB) without antidepressants
Number of subjects: 8910
Study 33989969 — intervention group
Group type: COMPARATOR
Intervention: Placebo + antidepressants
Number of subjects: 8910
Study 33989969 — intervention group
Group type: COMPARATOR
Intervention: Placebo without antidepressants
Number of subjects: 8910
Study 33214579 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-dissociation method (FM)
Number of subjects: 130
Study 33214579 — intervention group
Group type: COMPARATOR
Intervention: Conventional palpation method (PM)
Number of subjects: 130
Study 33214579 — intervention group
Group type: COMPARATOR
Intervention: Fat-dissociation method (FM) and Conventional palpation method (PM)
Number of subjects: 130
Study 34269720 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (16 mg) and 20% albumin (100 mL) at induction of anesthesia, then 200 mL of 20% albumin with each subsequent 1000 mL of crystalloid administered (Dex‐Alb group)
Number of subjects: 72
Study 34269720 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid fluid only with no dexamethasone (control group)
Number of subjects: 72
Study 34269720 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone and albumin (Dex‐Alb group)
Number of subjects: 72
Study 32009651 — intervention group
Group type: EXPERIMENTAL
Intervention: Anchor binders selected from a combinatorial library screened with a biotinylated ligand and validated with unlabeled ligand by bio-layer interferometry (BLI).
Number of subjects: 1000000000
Study 32009651 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimerization binders selected from anchor binder-ligand complexes for positive screening and unbound anchor binders for negative screening.
Number of subjects: 1000000000
Study 32035892 — intervention group
Group type: EXPERIMENTAL
Intervention: Omecamtiv mecarbil (25, 37.5, or 50 mg twice daily)
Number of subjects: 8000
Study 32035892 — intervention group
Group type: EXPERIMENTAL
Intervention: Omecamtiv mecarbil
Number of subjects: 8000
Study 32035892 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8000
Study 35500976 — intervention group
Group type: EXPERIMENTAL
Intervention: GM active trigger point dry needling (TrP‐DN) combined with conventional physiotherapy
Number of subjects: 29
Study 35500976 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 29
Study 32173107 — intervention group
Group type: EXPERIMENTAL
Intervention: Full MTM (complete MTM process)
Number of subjects: 1452
Study 32173107 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial MTM (incomplete MTM process)
Number of subjects: 1452
Study 32173107 — intervention group
Group type: COMPARATOR
Intervention: No MTM
Number of subjects: 1452
Study 34611715 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of any of seven symptoms for detecting influenza
Number of subjects: 2639
Study 34611715 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom severity model including cough, fever, muscle aches, sweating and/or chills, moderate to severe overall disease, age, abdominal pain, and sore throat
Number of subjects: 2639
Study 34118231 — intervention group
Group type: EXPERIMENTAL
Intervention: Asian applicants
Number of subjects: 342
Study 34118231 — intervention group
Group type: EXPERIMENTAL
Intervention: URM applicants
Number of subjects: 342
Study 34118231 — intervention group
Group type: EXPERIMENTAL
Intervention: White applicants
Number of subjects: 342
Study 33170590 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Temperature Plasma (LTP)
Number of subjects: 60
Study 33170590 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 33170590 — intervention group
Group type: EXPERIMENTAL
Intervention: Graft Stability (GS)
Number of subjects: 60
Study 33170590 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjunctival Autograft Inflammation (CAI)
Number of subjects: 60
Study 35877195 — intervention group
Group type: EXPERIMENTAL
Intervention: Favipiravir oral solution (200 mg/15 mL)
Number of subjects: 24
Study 35877195 — intervention group
Group type: COMPARATOR
Intervention: Favipiravir tablet (200 mg)
Number of subjects: 24
Study 32686253 — intervention group
Group type: EXPERIMENTAL
Intervention: PCSK9 levels on day 1
Number of subjects: 958
Study 32686253 — intervention group
Group type: EXPERIMENTAL
Intervention: PCSK9 levels across quartiles
Number of subjects: 958
Study 32686253 — intervention group
Group type: EXPERIMENTAL
Intervention: PCSK9 levels and PTX3 correlation
Number of subjects: 958
Study 32925999 — intervention group
Group type: COMPARATOR
Intervention: Open flap debridement with no further treatment (Group 1, n = 10)
Number of subjects: 25
Study 32925999 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezoelectric contouring of the furcation roof (Group 2, n = 10)
Number of subjects: 25
Study 32925999 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezoelectric contouring of the furcation roof and bone grafting (Group 3, n = 9)
Number of subjects: 25
Study 32925999 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezoelectric contouring of the furcation roof and bone grafting with coronally positioned flap (Group 4, n = 10)
Number of subjects: 25
Study 35739502 — intervention group
Group type: EXPERIMENTAL
Intervention: LUS‐monitored management (LUS‐m)
Number of subjects: 0
Study 35739502 — intervention group
Group type: COMPARATOR
Intervention: Standard care management (SC‐m)
Number of subjects: 0
Study 32696839 — intervention group
Group type: EXPERIMENTAL
Intervention: Involuntary breath stacking (IBS)
Number of subjects: 20
Study 32696839 — intervention group
Group type: COMPARATOR
Intervention: Voluntary breath stacking (VBS)
Number of subjects: 20
Study 36199782 — intervention group
Group type: EXPERIMENTAL
Intervention: Razumab (research group)
Number of subjects: 60
Study 36199782 — intervention group
Group type: COMPARATOR
Intervention: Compaq (control group)
Number of subjects: 60
Study 33462582 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 1 g orally once weekly for 3 weeks
Number of subjects: 125
Study 33462582 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline 100 mg twice daily for 21 days
Number of subjects: 125
Study 36484191 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (once a day, 6 times a week for 5 weeks, total of 30 times)
Number of subjects: 80
Study 36484191 — intervention group
Group type: COMPARATOR
Intervention: Sodium hyaluronate eye drops with routine cleaning of eyelid margin and hot compress of eyes
Number of subjects: 80
Study 33190133 — intervention group
Group type: EXPERIMENTAL
Intervention: ECC cycling training
Number of subjects: 24
Study 33190133 — intervention group
Group type: COMPARATOR
Intervention: CON cycling training
Number of subjects: 24
Study 36036087 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose vonoprazan-amoxicillin dual therapy (amoxicillin 1 g b.i.d. for 7 or 10 days, vonoprazan 20 mg b.i.d.)
Number of subjects: 41
Study 36036087 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vonoprazan-amoxicillin dual therapy (amoxicillin 1 g t.i.d. for 7 or 10 days, vonoprazan 20 mg b.i.d.)
Number of subjects: 41
Study 36036087 — intervention group
Group type: EXPERIMENTAL
Intervention: Helicobacter pylori-positive patients (L-VA and H-VA groups)
Number of subjects: 41
Study 36036087 — intervention group
Group type: COMPARATOR
Intervention: Helicobacter pylori-negative patients (normal controls)
Number of subjects: 41
Study 33565987 — intervention group
Group type: EXPERIMENTAL
Intervention: AMIS‐PPSHI scale (12 items)
Number of subjects: 1375
Study 33565987 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual health engagement and awareness subscale
Number of subjects: 1375
Study 33565987 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhancing dyadic communication subscale
Number of subjects: 1375
Study 33565987 — intervention group
Group type: EXPERIMENTAL
Intervention: Managing sexual health care subscale
Number of subjects: 1375
Study 33565987 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-factor PPSHI structure
Number of subjects: 1375
Study 32239541 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 1660
Study 33933206 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (400 mg–800 mg IV, depending on weight) plus usual standard of care
Number of subjects: 4116
Study 33933206 — intervention group
Group type: COMPARATOR
Intervention: Usual standard of care
Number of subjects: 4116
Study 33069063 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound measurement of the transversus abdominis muscle during abdominal hollowing
Number of subjects: 20
Study 32564957 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetic (lidocaine)
Number of subjects: 24
Study 32564957 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 24
Study 33176205 — intervention group
Group type: EXPERIMENTAL
Intervention: Typhoid Conjugate Vaccine (TCV) plus control vaccine (inactivated polio vaccine) and MCV-A 28 days later
Number of subjects: 150
Study 33176205 — intervention group
Group type: EXPERIMENTAL
Intervention: Typhoid Conjugate Vaccine (TCV) and MCV-A
Number of subjects: 150
Study 33176205 — intervention group
Group type: COMPARATOR
Intervention: Meningococcal Conjugate Vaccine (MCV-A) and control vaccine (inactivated polio vaccine)
Number of subjects: 150
Study 32279703 — intervention group
Group type: EXPERIMENTAL
Intervention: Checking‐in
Number of subjects: 91
Study 32279703 — intervention group
Group type: EXPERIMENTAL
Intervention: Camping‐out
Number of subjects: 91
Study 32279703 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 91
Study 34331162 — intervention group
Group type: EXPERIMENTAL
Intervention: bALND (breast axillary lymph node dissection)
Number of subjects: 832
Study 34331162 — intervention group
Group type: COMPARATOR
Intervention: sALND (standard axillary lymph node dissection)
Number of subjects: 832
Study 34331162 — intervention group
Group type: EXPERIMENTAL
Intervention: bALND
Number of subjects: 832
Study 34331162 — intervention group
Group type: COMPARATOR
Intervention: sALND
Number of subjects: 832
Study 33351885 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic mimicry of ANGPTL4 inhibition
Number of subjects: 61240
Study 33351885 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic mimicry of LPL enhancement
Number of subjects: 61240
Study 33351885 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic mimicry of ANGPTL3 inhibition
Number of subjects: 61240
Study 33351885 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic mimicry of ANGPTL4 inhibition and LPL enhancement
Number of subjects: 61240
Study 33351885 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic mimicry of ANGPTL3
Number of subjects: 61240
Study 35378069 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Number of subjects: 72
Study 35378069 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 33990500 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy
Number of subjects: 253
Study 33990500 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 253
Study 32861214 — intervention group
Group type: EXPERIMENTAL
Intervention: WSH interventions
Number of subjects: 1411
Study 32861214 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 1411
Study 35544387 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral lenacapavir for 14 days followed by subcutaneous lenacapavir every 6 months with optimized background therapy (Cohort 1)
Number of subjects: 72
Study 35544387 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous lenacapavir every 6 months with optimized background therapy (Cohort 2)
Number of subjects: 72
Study 35544387 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 14 days followed by oral lenacapavir and then subcutaneous lenacapavir with optimized background therapy (Cohort 1)
Number of subjects: 72
Study 32142135 — intervention group
Group type: EXPERIMENTAL
Intervention: Action Observation (AO)
Number of subjects: 24
Study 32142135 — intervention group
Group type: EXPERIMENTAL
Intervention: Action Observation + Motor Imagery (AO+MI)
Number of subjects: 24
Study 32142135 — intervention group
Group type: COMPARATOR
Intervention: Placebo Observation (PO)
Number of subjects: 24
Study 34171877 — intervention group
Group type: EXPERIMENTAL
Intervention: Checklist
Number of subjects: 103
Study 34171877 — intervention group
Group type: EXPERIMENTAL
Intervention: Global Rating Scale (GRS)
Number of subjects: 103
Study 34408060 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label placebo (OLP) treatment
Number of subjects: 30
Study 34408060 — intervention group
Group type: COMPARATOR
Intervention: Conventional OLP rationale
Number of subjects: 30
Study 33226999 — intervention group
Group type: EXPERIMENTAL
Intervention: Protease inhibitor
Number of subjects: 263
Study 33226999 — intervention group
Group type: COMPARATOR
Intervention: Non-nucleoside reverse transcriptase inhibitor
Number of subjects: 263
Study 33226999 — intervention group
Group type: COMPARATOR
Intervention: Protease inhibitor vs. Non-nucleoside reverse transcriptase inhibitor
Number of subjects: 263
Study 34872717 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron (ferric carboxymaltose 1000 mg i.v.)
Number of subjects: 98
Study 34872717 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 98
Study 33563165 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyberspace-based education for one month
Number of subjects: 86
Study 33563165 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 86
Study 32346280 — intervention group
Group type: EXPERIMENTAL
Intervention: Black stroke survivors
Number of subjects: 1002
Study 32346280 — intervention group
Group type: EXPERIMENTAL
Intervention: Aging, being female, being Black, and longer time since stroke
Number of subjects: 1002
Study 32346280 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbidities
Number of subjects: 1002
Study 32346280 — intervention group
Group type: EXPERIMENTAL
Intervention: Black race
Number of subjects: 1002
Study 33503074 — intervention group
Group type: EXPERIMENTAL
Intervention: ART (antiretroviral therapy)
Number of subjects: 300